STAT3-mediated apoptotic-enhancing function of sclareol against breast cancer cells and cell sensitization to cyclophosphamide

Document Type : Research article

Authors

1 Department of Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Department of Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.

3 Department of Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

4 Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Sclareol is an organic compound with potential anti-tumor effects against various cancer types. However, its precise molecular mechanism in suppression of tumor growth has not been fully elucidated. In the present study the anti-proliferative and apoptosis-inducing effects of sclareol with cyclophosphamide was investigated in breast cancer cells and the involvement of JAK/STAT pathway was evaluated. For this purpose, MCF-7 breast cancer cells were cultured and treated with various concentrations of sclareol to determine its IC50. Cell viability was measured by MTT assay and apoptosis was assessed by fluocytometric analysis of annexin V binding. Gene and protein expression were examined by real-time PCR and Western blotting, respectively. The activity of caspase enzymes was also measured. The results showed that sclareol significantly reduced cell viability and triggered cell death and its coadministration with cyclophosphamide enhanced its anti-cancer properties. Additionally, sclareol up-regulated the expression of p53 and BAX while reduced the expression of Bcl-2. Caspases 8 and 9 were also activated by sclareol, an effect that was augmented by cyclophosphamide. Docking studies indicated an interaction between sclareol and STAT3 which was proved by attenuation of STAT3 phosphorylation after treatment of cells with sclareol. Sclareol was also capable of suppressing the function of IL-6 in modulating the expression of apoptosis-associated genes. Altogether these data suggest the potential of sclareol as an anti-cancer agent and demonstrate that combination of sclareol with cyclophosphamide might serve as an effective chemotherapeutic approach resulting in improvements in the treatment of breast cancer.

Graphical Abstract

STAT3-mediated apoptotic-enhancing function of sclareol against breast cancer cells and cell sensitization to cyclophosphamide

Keywords

Main Subjects



1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, TorreLA and Jemal A. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortalityworldwide for 36 cancers in 185 countries. CA(2018) 68: 394-424.
2. Barabadi H, Mahjoub MA, Tajani B, Ahmadi A,Junejo Y and Saravanan M. Emerging theranosticbiogenic silver nanomaterials for breast cancer: Asystematic review. J. Clust. Sci. (2019) 30: 259-79.
3. Siegel RL, Miller KD and Jemal A. Cancer statistics,2019. CA (2019) 69: 7-34.
4. Farhood B, Geraily G and Alizadeh A. Incidenceand mortality of various cancers in Iran and compareto other countries: a review article. Iran. J. PublicHealth (2018) 47: 309.
5. Waks AG and Winer EP. Breast Cancer Treatment:A ReviewBreast Cancer Treatment in 2019BreastCancer Treatment in 2019. JAMA (2019) 321: 288-300.
6. Rabzia A, Khazaei M, Rashidi Z and KhazaeiMR. Synergistic anticancer effect of paclitaxel andnoscapine on human prostate cancer cell lines. Iran.J. Pharm. Res. (2017) 16: 1432.
7. Fanian M, Bahmani M, Mozafari M, Naderi S,Zareie MA, Okhovat MA, Saberzadeh J, DehshahriA and Takhshid MA. The Synergistic Effects ofCelecoxib and Sodium Valproate on Apoptosis andInvasiveness Behavior of Papillary Thyroid CancerCell Line In-vitro. Iran. J. Pharm. Res. (2018)17:1008.
8. Park JH, Im SA, Byun JM, Kim KH, Kim JS, ChoiIS, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY andKim TY. Cyclophosphamide, Methotrexate, and
5-Fluorouracil as Palliative Treatment for HeavilyPretreated Patients with Metastatic Breast Cancer:A Multicenter Retrospective Analysis. J. BreastCancer (2017) 20: 347-55.
9. Fernandes R, Mazzarello S, Stober C, VandermeerL, Dudani S, Ibrahim MFK, Majeed H, Perdrizet K,Shorr R, Hutton B, Fergusson D and Clemons M.Optimal primary febrile neutropenia prophylaxisfor patients receiving docetaxel–cyclophosphamidechemotherapy for breast cancer: a systematic review.Breast Cancer Res. Treat. (2017) 161: 1-10.
10. Emadi A, Jones RJ and Brodsky RA.Cyclophosphamide and cancer: golden anniversary. 411Afshari H et al. / IJPR (2020), 19 (1): 398-412Nat. (2009) 6: 638.
11. Stoll B. Evaluation of cyclophosphamide dosageschedules in breast cancer. Br. J. Cancer. (1970)24:475.
12. Ahmed AR and Hombal SM. Cyclophosphamide(Cytoxan): a review on relevant pharmacologyand clinical uses. J. Am. Acad. Dermatol. (1984)11:1115-26.
13. Hatiboglu MA, Kong LY, Wei J, Wang Y, McEneryKA, Fuller GN, Qiao W, Davies MA, Priebe Wand Heimberger AB. The tumor microenvironmentexpression of p‐STAT3 influences the efficacyof cyclophosphamide with WP1066 in murinemelanoma models. Int. J. Cancer. (2012) 131:8-17.
14. Duan G, Hou S, Ji J and Deng B. The study of sclareolin inhibiting proliferation of osteosarcoma cellsby apoptotic induction and loss of mitochondrialmembrane potential. Canc. Biomarkers. (2018) 22:29-34.
15. Borges GSM, Silva JO, Fernandes RS, de SouzaAM, Cassali GD, Yoshida MI, Leite EA, de BarrosALB and Ferreira LAM. Sclareol is a potentenhancer of doxorubicin: Evaluation of the freecombination and co-loaded nanostructured lipidcarriers against breast cancer. Life Sci. (2019)232:116678.
16. Dimas K, Papadaki M, Tsimplouli C, HatziantoniouS, Alevizopoulos K, Pantazis P and Demetzos C.Labd-14-ene-8,13-diol (sclareol) induces cell cyclearrest and apoptosis in human breast cancer cellsand enhances the activity of anticancer drugs.Biomed. Pharmacother. (2006) 60:127-33.
17. Masjedi A, Hashemi V, Hojjat-Farsangi M,Ghalamfarsa G, Azizi G, Yousefi M and JadidiNiaragh F. The significant role of interleukin-6 andits signaling pathway in theimmunopathogenesisand treatment of breast cancer. Biomed.Pharmacother. (2018) 108:1415-24.
18. Noori S, Hassan ZM and Salehian O. Sclareolreduces CD4+ CD25+ FoxP3+ Treg cells in abreast cancer model in vivo. Iran. J. Immunol.
(2013) 10:10-21.19. Becker S, Groner B and Muller CW. Threedimensional structure of the Stat3beta homodimerbound to DNA. Nature (1998) 394:145-51.
20. Masjedi A, Hashemi V, Hojjat-Farsangi M,Ghalamfarsa G, Azizi G, Yousefi M and JadidiNiaragh F. The significant role of interleukin-6 andits signaling pathway in the immunopathogenesisand treatment of breast cancer. Biomed.Pharmacother. (2018) 108:1415-24.
21. Lee HH, Jung J, Moon A, Kang H and Cho H.Antitumor and Anti-Invasive Effect of Apigenin onHuman Breast Carcinoma through Suppression ofIL-6 Expression. Int. J. Mol. (2019) 20:3143.
22. Yuan J, Zhang F and Niu R. Multiple regulationpathways and pivotal biological functions ofSTAT3 in cancer. Sci. Rep. (2015) 5:17663.
23. Cava C, Bertoli G and Castiglioni I. Integratinggenetics and epigenetics in breast cancer:Biological insights, experimental, computationalmethods and therapeutic potential. BMC Syst. Biol.(2015) 9:62.
24. Nicholson RI and Johnston SR. Endocrine therapy--current benefits and limitations. Breast CancerRes. Treat. (2005) 93:S3-10.
25. Joseph M, Nora G, Masaru T, Judith H, Elke B-L,Peter M, Joseph D, Remigijus D and Maria JUF:Inhibition of Multidrug Resistance of CancerCells by Natural Diterpenes, Triterpenes andCarotenoids. Curr. Pharm. (2006) 12:287-311.
26. KC S, Dhungana RK, Aryal V and Giri R. ConciseSynthesis of a Potential 5-Lipoxygenase ActivatingProtein (FLAP) Inhibitor and Its Analogs throughLate-Stage Alkene Dicarbofunctionalization. Org.Process. Res. Dev. (2019) 23: 1686-94.
27. Qin J-J, Yan L, Zhang J and Zhang W-D. STAT3as a potential therapeutic target in triple negativebreast cancer: a systematic review. J. Exp. Clin.Cancer Res. (2019) 38:195.
28. Kim JW, Gautam J, Kim JE, Kim J and KangKW. Inhibition of tumor growth and angiogenesisof tamoxifen‑resistant breast cancer cells byruxolitinib, a selective JAK2 inhibitor. Oncol. Lett.
(2019) 17:3981-9.
29. Dimas K, Papadaki M, Tsimplouli C, HatziantoniouS, Alevizopoulos K, Pantazis P and Demetzos C.Labd-14-ene-8,13-diol (sclareol) induces cell cyclearrest and apoptosis in human breast cancer cellsand enhances the activity of anticancer drugs.Biomed. Pharmacother. (2006) 60:127-33.
30. Wang L, He HS, Yu HL, Zeng Y, Han H, He N, LiuZG, Wang ZY, Xu SJ and Xiong M. Sclareol, a plantditerpene, exhibits potent antiproliferative effectsvia the induction of apoptosis and mitochondrialmembrane potential loss in osteosarcoma cancercells. Mol. Med. Rep. (2015) 11:4273-4278.
31. Zhang T, Wang T and Cai P. Sclareol inhibitscell proliferation and sensitizes cells to theantiproliferative effect of bortezomib viaupregulating the tumor suppressor caveolin-1
in cervical cancer cells. Mol. Med. Rep. (2017)15:3566-3574.
32. Baig S, Seevasant I, Mohamad J, Mukheem A, HuriHZ and Kamarul T. Potential of apoptotic pathwaytargeted cancer therapeutic research: Where do westand? Cell Death Dis. (2016) 7:e2058-e2058.412Apoptotic effects of sclareol in breast cancer cells
33. Um H-D. Bcl-2 family proteins as regulators ofcancer cell invasion and metastasis: a reviewfocusing on mitochondrial respiration and reactiveoxygen species. Oncotarget. (2016) 7:5193-5203.
34. Du C, Zhang X, Yao M, Lv K, Wang J, ChenL, Chen Y, Wang S and Fu P. Bcl-2 promotes metastasis through the epithelial-to-mesenchymaltransition in the BCap37 medullary breast cancercell line. Oncol. Lett. (2018). 15:8991-8898.
35. García-Aranda M, Pérez-Ruiz E and RedondoM. Bcl-2 Inhibition to Overcome Resistance toChemo- and Immunotherapy. Int. J. Mol. Sci.(2018) 19:3950.
36. Del Poeta G, Venditti A, Del Principe MI, MaurilloL, Buccisano F, Tamburini A, Cox MC, Franchi A,Bruno A and Mazzone C. Amount of spontaneousapoptosis detected by Bax/Bcl-2 ratio predictsoutcome in acute myeloid leukemia (AML):Presented in part at the 42nd annual meeting of theAmerican Society of Hematology, San Francisco,CA, December 1-5, 2000.46. Blood (2003)101:2125-31.
37. Yoshino T, Shiina H, Urakami S, Kikuno N, YonedaT, Shigeno K and Igawa M. Bcl-2 expression as apredictive marker of hormone-refractory prostatecancer treated with taxane-based chemotherapy.Clin. Cancer Res. (2006) 12:6116-24.
38. Minn AJ, Rudin CM, Boise LH and ThompsonCB. Expression of bcl-xL can confer a multidrugresistance phenotype. Blood (1995) 86:1903-10.
39. Jana S, Hsieh AC and Gupta R. Reciprocalamplification of caspase-3 activity by nuclearexport of a putative human RNA-modifyingprotein, PUS10 during TRAIL-induced apoptosis.Cell Death Dis. (2017) 8: e3093-e3093.
40. Wang K, Zhang C, Bao J, Jia X, Liang Y, WangX, Chen M, Su H, Li P and Wan JB. Synergisticchemopreventive effects of curcumin and berberineon human breast cancer cells through inductionof apoptosis and autophagic cell death. Sci. Rep.(2016) 6: 26064.
41. Jänicke RU. MCF-7 breast carcinoma cells donot express caspase-3. Breast Cancer Res. Treat.(2009) 117:219-221.
42. Johnston PA and Grandis JR. STAT3 signaling:anticancer strategies and challenges. Mol. Interv.(2011) 11:18-26.
43. Huynh J, Chand A, Gough D and Ernst M.Therapeutically exploiting STAT3 activity in
cancer—using tissue repair as a road map. Nat.
(2019) 19: 82-96.
44. Berishaj M, Gao SP, Ahmed S, Leslie K, AlAhmadie H, Gerald WL, Bornmann W andBromberg JF. Stat3 is tyrosine-phosphorylated
through the interleukin-6/glycoprotein 130/Januskinase pathway in breast cancer. Breast CancerRes. (2007) 9: R32.
45. Dutta P, Sabri N, Li J and Li WX. Role of STAT3 inlung cancer. JAK-STAT. (2015) 3:e999503-e999503.
46. Yoshikawa T, Miyamoto M, Aoyama T, Soyama H,Goto T, Hirata J, Suzuki A, Nagaoka I, Tsuda H,Furuya K and Takano M. JAK2/STAT3 pathway asa therapeutic target in ovarian cancers. Oncol. Lett.(2018) 15:5772-80.
47. Wei N, Li J, Fang C, Chang J, Xirou V, SyrigosNK, Marks BJ, Chu E and Schmitz JC. Targetingcolon cancer with the novel STAT3 inhibitorbruceantinol. Oncogene (2019) 38:1676-87.
48. Qin J-J, Yan L, Zhang J and Zhang WD. STAT3as a potential therapeutic target in triple negativebreast cancer: a systematic review. J. Exp. Clin.Cancer. Res. (2019) 38:195.
49. Niu G, Wright KL, Huang M, Song L, Haura E,Turkson J, Zhang S, Wang T, Sinibaldi D, CoppolaD, Heller R, Ellis LM, Karras J, Bromberg J,Pardoll D, Jove R and Yu H. Constitutive Stat3activity up-regulates VEGF expression and tumorangiogenesis. Oncogene (2002) 21: 2000-8.
50. Chen Z and Han ZC. STAT3: a critical transcriptionactivator in angiogenesis. Med. Res. Rev. (2008)28:185-200.
51. Krstić M, Stojanović NM, Stojnev S, RadenkovićG, Čukuranović Kokoris J, Mladenović B andJanković Veličković L. Interplay between STAT3,Cell Adhesion Molecules and AngiogenesisRelated Parameters in Gastric Carcinoma. DoesSTAT3 Really Have a Prognostic Value? Medicina(2019) 55:300.